Research ArticleArticle
Characterization of Fasiglifam-Related Liver Toxicity in Dogs
Akifumi Kogame, Yuu Moriya, Ikuo Mori, Liping Pan, Akio Morohashi, Takuya Ebihara, Hideo Fukui, Yoshihiko Tagawa and Leslie Z. Benet
Drug Metabolism and Disposition May 2019, 47 (5) 525-534; DOI: https://doi.org/10.1124/dmd.118.084889
Akifumi Kogame
Drug Metabolism and Pharmacokinetics Research Laboratories (A.K., Y.M., A.M., T.E., Y.T.) and Drug Safety Research Laboratories (I.M., H.F.), Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan; Takeda Development Center Americas, Inc., Deerfield, Illinois (L.P.); and Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, California (L.Z.B.)
Yuu Moriya
Drug Metabolism and Pharmacokinetics Research Laboratories (A.K., Y.M., A.M., T.E., Y.T.) and Drug Safety Research Laboratories (I.M., H.F.), Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan; Takeda Development Center Americas, Inc., Deerfield, Illinois (L.P.); and Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, California (L.Z.B.)
Ikuo Mori
Drug Metabolism and Pharmacokinetics Research Laboratories (A.K., Y.M., A.M., T.E., Y.T.) and Drug Safety Research Laboratories (I.M., H.F.), Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan; Takeda Development Center Americas, Inc., Deerfield, Illinois (L.P.); and Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, California (L.Z.B.)
Liping Pan
Drug Metabolism and Pharmacokinetics Research Laboratories (A.K., Y.M., A.M., T.E., Y.T.) and Drug Safety Research Laboratories (I.M., H.F.), Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan; Takeda Development Center Americas, Inc., Deerfield, Illinois (L.P.); and Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, California (L.Z.B.)
Akio Morohashi
Drug Metabolism and Pharmacokinetics Research Laboratories (A.K., Y.M., A.M., T.E., Y.T.) and Drug Safety Research Laboratories (I.M., H.F.), Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan; Takeda Development Center Americas, Inc., Deerfield, Illinois (L.P.); and Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, California (L.Z.B.)
Takuya Ebihara
Drug Metabolism and Pharmacokinetics Research Laboratories (A.K., Y.M., A.M., T.E., Y.T.) and Drug Safety Research Laboratories (I.M., H.F.), Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan; Takeda Development Center Americas, Inc., Deerfield, Illinois (L.P.); and Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, California (L.Z.B.)
Hideo Fukui
Drug Metabolism and Pharmacokinetics Research Laboratories (A.K., Y.M., A.M., T.E., Y.T.) and Drug Safety Research Laboratories (I.M., H.F.), Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan; Takeda Development Center Americas, Inc., Deerfield, Illinois (L.P.); and Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, California (L.Z.B.)
Yoshihiko Tagawa
Drug Metabolism and Pharmacokinetics Research Laboratories (A.K., Y.M., A.M., T.E., Y.T.) and Drug Safety Research Laboratories (I.M., H.F.), Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan; Takeda Development Center Americas, Inc., Deerfield, Illinois (L.P.); and Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, California (L.Z.B.)
Leslie Z. Benet
Drug Metabolism and Pharmacokinetics Research Laboratories (A.K., Y.M., A.M., T.E., Y.T.) and Drug Safety Research Laboratories (I.M., H.F.), Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan; Takeda Development Center Americas, Inc., Deerfield, Illinois (L.P.); and Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, California (L.Z.B.)

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Fasiglifam-Related Liver Toxicity in Dogs
Akifumi Kogame, Yuu Moriya, Ikuo Mori, Liping Pan, Akio Morohashi, Takuya Ebihara, Hideo Fukui, Yoshihiko Tagawa and Leslie Z. Benet
Drug Metabolism and Disposition May 1, 2019, 47 (5) 525-534; DOI: https://doi.org/10.1124/dmd.118.084889
Research ArticleArticle
Fasiglifam-Related Liver Toxicity in Dogs
Akifumi Kogame, Yuu Moriya, Ikuo Mori, Liping Pan, Akio Morohashi, Takuya Ebihara, Hideo Fukui, Yoshihiko Tagawa and Leslie Z. Benet
Drug Metabolism and Disposition May 1, 2019, 47 (5) 525-534; DOI: https://doi.org/10.1124/dmd.118.084889
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement